Originally published June 7.
By Turna Ray
CHICAGO — Pfizer presented new data on several investigational targeted drugs at the American Society of Clinical Oncology's annual meeting here this week, making good on its previously expressed desire to increasingly apply pharmacogenomic strategies to its drug development process.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
